mRNAã¯ã¯ãã³ã¸ã®ç念ã¼è質ããç²åãåµå·£ã«èç©ï¼
ã¯ããã«
COVID-19-mRNAã¯ã¯ãã³ã«ã¤ãã¦ã¯ã主ã¨ãã¦å®å ¨æ§ã®é¢ããããã¤ãã¿ã¼ãªã©ã®SNSä¸ã§ãã¾ãã¾ãªæ¸å¿µãåãåºãã£ã¦ãã¾ããã¾ããæ ¹æ ã®ãªãæãããªããã¨æãããæ å ±ã¾ã§ãé£ã³äº¤ã£ã¦ãã¾ããå½ãå°é家ã¯å½ç¶ãªãããããã®åããããå¦å®ããã¯ã¯ãã³æ¥ç¨®ãæ¨å¥¨ãã¦ãã¾ããæ²³éæ å½å¤§è£ãããæ å ±ãæã¡æ¶ãè¦è§£ãèªèº«ã®ããã°ã§ç¤ºãã¾ãã [1, 2]ã
ãããããã¤ãã¿ã¼ãããã°ä¸ã§ã®å®å ¨æ§ã¸ã®æ¸å¿µã®ã³ã¡ã³ãã¯ç¸å¤ãããã§ããæ°ããã¯ã¯ãã³ã«å¯¾ããæ¸å¿µãããã¯ãã¤ããããã¨ã§ãããä»åã®mRNAã¯ã¯ãã³ã¯ç·æ¥ä½¿ç¨è¨±å¯ãããåä¾ã®ãªãã¯ã¯ãã³ã¨ãããã¨ã§ç¹å¥ã ã¨è¨ããã§ããããã¨ãã«ãç´°èãã¯ã¯ãã³ã®çç£å·¥å ´ã¨ãªãããã»ã¹ã«å¯¾ããå®å ¨æ§ã®å¯©æ»ãè¡ãªãããªãã¾ã¾ãæ¥ç¨®ãæ¨å¥¨ããã¦ããã¨ãããã¨ãæç¶ãä¸åé¡ã ã¨è¨ãã¾ããããã°ãä»ã¾ãã«ä¸çä¸ã§äººä½å®é¨ä¸ãªããã§ãã
ããã¦æ¥æ¬ã§è¨ãã°ãææãªã¹ã¯ã«å¯¾ããã¯ã¯ãã³æ¥ç¨®ã®å©çã®ç¨åº¦ãä¸æ確ãªã¾ã¾æ¥ç¨®ãè¡ãªããã¦ãã¾ããå»çå¾äºè ãé«é½¢è ãåºç¤ç¾æ£ã®ãã人ã«å¯¾ããã¯ã¯ãã³æ¥ç¨®ã¯å©çãããã¨æãã¾ãããè¥å¹´å±¤ãåä¾ãå¦å¨ å¯è½ãªå¥³æ§ã«å¯¾ãã¦ã¯æããã¦ã©ããªã®ã ãããï¼ã¨ããçåãããã¾ãã
åã®ããã°è¨äºã§ãæ ¸é ¸ã¯ã¯ãã³ï¼ã¨ãã«mRNAã¯ã¯ãã³ï¼ã«é¢ããå®å ¨æ§ã«ã¤ãã¦èå¯ãã¾ããï¼âæ ¸é ¸ã¯ã¯ãã³ã¸ã®çåã¼ããã¼ã³å士ã®ä¸»å¼µãèãããCOVID-19ã¯ã¯ãã³ã¯å¦å¨ ãçæ®ã¸ã®å½±é¿ããããï¼ï¼ãå½éçãªå°é家ã«ãããmRNAã¯ã¯ãã³ãå¦å¨ ãçæ®ã«åã¼ãæªå½±é¿ã¯ç¾å¨ã®ã¨ããèªããããªããã¨ããè¦è§£ãç´¹ä»ãã¾ããã
ãã®ä¸ã§ãããã§ã¯ããããã¦mRNAã¯ã¯ãã³ã®å®å ¨æ§ã«å¯¾ããç念ãåãèãã¦ã¿ããã¨æãã¾ãã
1. ãã¡ã¤ã¶ã¼ã¯ã¯ãã³ã«å¯¾ããåã®çµç·¯
ãã¡ã¤ã¶ã¼ç¤¾ã®mRNAã¯ã¯ãã³ã«ã¤ãã¦SNSä¸ã§åããã¦ããæ å ±ã®ä¸ã¤ã¨ãã¦ããã¯ã¯ãã³ã®è質ããç²åãåµå·£ã«èç©ãããã¨ããã®ãããã¾ãã
äºã®å§ã¾ãã¯ãã²ã«ã大å¦ãªã³ã¿ãªãªç£å»ç§å¤§å¦ã®ã¦ã¤ã«ã¹å ç«å¦è ããã¤ã©ã ã»ãã©ã¤ãã«ï¼Byram Bridleï¼å士ãããã¡ã¤ã¶ã¼ç¤¾ã«ããè¬ç©åæ ç 究ã®æ¥µç§ãã¼ã¿ã®ã³ãã¼ãå ¥æãããããä»æï¼6æï¼åãã«å ¬éãããã¨ã«ããã¾ããããã¯æ¥æ¬æ¿åºã«å¯¾ãã¦ããã¡ã¤ã¶ã¼ã®æªå ¬éãã¼ã¿ãæ±ããæ å ±å ¬éè«æ±ãè¡ã£ãçµæãå ¥æãããã®ã ã¨ããã¦ãã¾ãã
ãã®å°ãåãå½¼ã¯ãã«ããã®ã©ã¸ãªçªçµå¸ä¼è ã¢ã¬ãã¯ã¹ã»ãã¢ã½ã³ã®ã¤ã³ã¿ãã¥ã¼ã«å¿ãã¦ãã¾ããããã¦ãç§ãã¡ã¯å¤§ããªééããç¯ãããã¹ãã¤ã¯ã¿ã³ãã¯ã¯åªããæ¨çæåã ã¨æã£ã¦ããããããèªä½ãæ¯ç´ ã§ããããããç¥ããªãã¾ã¾ãã¯ã¯ãã³ã¨ãã¦æ¥ç¨®ãããã¨ã§ã誤ã£ã¦æ¯ç´ ãæ¥ç¨®ãã¦ãã¾ã£ããã¨ãã主æ¨çºè¨ããã¾ããã
ãã®ãã©ã¤ãã«å士ã®çºè¨ã¯ãSNSä¸ã§ã¾ãããéã«æ¡æ£ãã¾ãããä»ã®å°é家ã¯ããã«åå¿ããããã£ã¦å½¼ã®çºè¨å 容ï¼ã¹ãã¤ã¯ã¿ã³ãã¯è³ªã¯æ¯ç´ ï¼ãå¦å®ãã¾ãããã¾ããå¤ãã®ãã¡ã¯ããã§ãã¯ã®ãµã¤ããããããã誤ããã¨ããå¤æãä¸ãã¦ãã¾ã [3, 4, 5]ãã¨ã¯ãããå½¼ãå ¬éãããã¡ã¤ã¶ã¼ç¤¾ã®æªå ¬éãã¼ã¿ã¯ç念ããã¤å 容ã«ãªã£ã¦ãã¾ãã
ã¡ãªã¿ã«ãéé¢ã®ã¹ãã¤ã¯ã¿ã³ãã¯è³ªèªèº«ã®æ¯æ§ã«é¢ãããããªç¶æ³è¨¼æ ã示ãè«æã¯ããã¤ãåºã¦ãã¾ãããã¬ããªã³ã段éã§ãããCOVID-19æ£è ã§ã¯ã循ç°ä¸ã®ã¹ãã¤ã¯ã¿ã³ãã¯ã®åå¨ãååºäº¢é²ã®ä¸å ã¨ãªã£ã¦ãããç·æº¶ã®é害ãå¼ãèµ·ããã¦ããå¯è½æ§ã示åããã¦ãã¾ã [6]ãã¾ããã¹ãã¤ã¯ã¿ã³ãã¯è³ªåç¬ã§ãACE2ãä½ä¸ããããã®çµæãããã³ã³ããªã¢æ©è½ãé»å®³ãããã¨ã§ãè¡ç®¡å ç®ç´°èã«ãã¡ã¼ã¸ãä¸ãããã¨ãå ±åããã¦ãã¾ã [7]ã
6æ10æ¥ãmRNAã¯ã¯ãã³æè¡ã®çã¿ã®è¦ªã§ããããã¼ãã»ããã¼ã³ï¼R. Maloneï¼å士ã¯ãé²åçç©å¦è ã®ãã¬ããã»ã¯ã¤ã³ã¹ã¿ã¤ã³ï¼B. Weinsteinï¼å士ã¨ã¨ãã«ãDark Horse Podcast ã§3æéã«ããã£ã¦å¯¾è«ãããã¡ã¤ã¶ã¼ç¤¾ã¨ã¢ãã«ã社ã®mRNAã¯ã¯ãã³ã«é¢é£ããè¤æ°ã®å®å ¨æ§ã®æ¸å¿µã«ã¤ãã¦è°è«ãã¾ãããããã¼ã³å士ã«ã¤ãã¦ã¯å ã®ããã°è¨äºã§ç´¹ä»ãã¦ãã¾ãï¼âæ ¸é ¸ã¯ã¯ãã³ã¸ã®çåã¼ããã¼ã³å士ã®ä¸»å¼µãèããï¼
ãã®ããããã£ã¹ãã§ã¯ãããã¼ã³å士ãã¯ã¤ã³ã¹ã¿ã¤ã³å士ãæè¡èµ·æ¥å®¶ã®ã¹ãã£ã¼ãã»ã«ã¼ã·ã¥æ°ã®3人ããç©è°ãé¸ããæ¥æ¬ç±æ¥ã®ãã¡ã¤ã¶ã¼ç¤¾ã®è¬ç©åæ ç 究ãã¼ã¿ã®æå³ã«ã¤ãã¦è§¦ãã¦ãã¾ãããDefenderãããã詳ããå ±ãã¦ãã¾ã [8]ã
ãã®ã¦ã§ãè¨äºã«ããã°ããã¡ã¤ã¶ã¼ç¤¾ã®ç 究ãå ¬éãããåã¯ãè¦å¶å½å±ãã¯ã¯ãã³éçºè ã¯ãmRNAã¯ã¯ãã³ã§çæãããã¹ãã¤ã¯ã¿ã³ãã¯è³ªã¯ã注å°ãããè©ã«çã¾ããçç©å¦çæ´»æ§ã¯ãªãã¨ä¿¡ãã¦ããããå°ãªãã¨ã表é¢çã«ã¯ãã®ããã«è£ ã£ã¦ããããã§ãã
ã¨ãããããã©ã¤ãã«å士ãå ¥æãã極ç§ãã¼ã¿ã«ããã°ãã¯ã¯ãã³ã®è質ããç²åã¯ã注å°ãããä¸è§çã«çã¾ãããå ¨èº«ã循ç°ããè¾èã骨é«ãèèãå¯è ãããã¦ãããªãé«ãæ¿åº¦ãã§åµå·£ãå«ãèå¨ãçµç¹ã«é«æ¿åº¦ã§èç©ããã¦ãããã¨ã示ããã®ã ã¨ãDefenderã¯ä¼ãã¦ãã¾ããããã¯ãéçºè ã主張ãã¦ãããã¨ã¨ã¯ã¾ã£ããç°ãªããã®ã§ãã
2. ãã¡ã¤ã¶ã¼ã®è¬ç©åæ ç 究ã®å 容ã¨è§£é
ããã§ã¯ããã©ã¤ãã«å士ãå ¬éããç 究ã³ãã¼ããã¡ã¤ã¶ã¼è¬ç©åæ 試é¨æ¦è¦ãããå®éã«è¦ã¦ã¿ã¾ããããããã¯ãSARS-CoV-2 mRNA Vaccine (BNT162, PF-07302048) 2.6.4 ã¨åä»ããããææ¸ã®ã³ãã¼ã§ãããã¬ã¤ã¢ã¦ããä¸é¨å´©ããã¯ãå¡ãé¨åããã£ã¦è¦ã¥ããã§ãããå½è©²é¨åã ããæãåºãã¦èãã¦ã¿ããã¨æãã¾ãããã®è©¦é¨ã®æ¦è¦ã¯åçå´åçã®å ±åæ¸ [9] ã§ãè¦ããã¨ãã§ãã¾ãã
ä¸ã®ä¸ã§ã¯mRNAã¯ã¯ãã³ã¨ä¸è¨ã§è¡¨ããã¦ãã¾ãããmRNAãã®ãã®ã¯ä½å ã§"ã¯ã¯ãã³"ã®æ¬ä½ã§ããã¹ãã¤ã¯ã¿ã³ãã¯ã製é ããããã«æ示ãããã®ã§ããå®éã¯mRNAãè質ã§ã³ã¼ãã£ã³ã°ããè質ããç²åã¨ãã¦ãè ã®çèå ã«æ³¨å°ãã¾ããããè質ããç²åãèå¨ãçµç¹ã®ä¸ã«è¦ã¤ããã°ãçèé åã«çã¾ãããããããã®å ´æã«"è¬"ãå±ãããã¨ã«ãªãã¾ãã
ãã¡ã¤ã¶ã¼ã¯ãããã©ããã使ã£ãåç©å®é¨ã§èª¿ã¹ã¦ãã¾ããã«ã·ãã§ã©ã¼ã¼ãã³ã¼ãããmRNAãä¸é¨ããªãã¦ã ã§æ¨èããè質ã§ã³ã¼ãã£ã³ã°ãããã®è質ããç²åãã©ããã«çè注å°ããåèå¨ãçµç¹ã«ã©ã®ããã«å°éãããã調ã¹ã¾ãããè質ã®åå¸ã¯åèå¨ã»çµç¹ã®æ¾å°æ§æ´»æ§ãã·ã³ãã¬ã¼ã·ã§ã³ã«ã¦ã³ã¿ã¼ã§æ¸¬å®ãããã¨ã§ç¢ºããã¾ãããã¾ããUPLC-質éåæã§è質ã®åå¸ãå解ã追跡ãã¦ãã¾ããmRNAã®çºç¾ã¯ã«ã·ãã§ã©ã¼ã¼çºå ã®ã¤ã¡ã¼ã¸ã³ã°ã§è¦ã¦ãã¾ãã
表1ã«ã主ãªèå¨ã§ã®åå¸ãæãåºãã¦ç¤ºãããã¼ã¿ã示ãã¾ãã
表1. ã©ããã«æ¨¡æ¬mRNAã¯ã¯ãã³ï¼è質ããç²åï¼ãæ¥ç¨®ããå¾ã®èå¨ã»çµç¹å ã®åå¸ï¼ãã¡ã¤ã¶ã¼è¬ç©åæ 試é¨æ¦è¦ã«åºã¥ãã¦çè ä½è¡¨ï¼
è質ããç²åã¯ãå½ç¶ãªãã注å°çèé¨åã§ã®æ¿åº¦ãæãé«ãæ¤åºããã¾ãããã4æé以å ã«å ¨èº«ã循ç°ããå ¨è¡ä¸ã«æ¤åºããããã®å¾ãèèãè¾èãåµå·£ã骨é«ããªã³ãç¯ã«é«æ¿åº¦ã§å®çãã¾ããï¼è¡¨1æªè¡¨ç¤ºï¼[8]ã表1å·¦ããã¯ãæéçµéã¨ã¨ãã«ãè質ãèèãè¾èãåµå·£ã«é«æ¿åº¦ã«èç©ããã¦ãããã¨ãè¦ã¦ã¨ãã¾ãããããã48æéã¾ã§ã®ãã¼ã¿ããå ¬è¡¨ããã¦ããªãã®ã§ããã以éã©ããªã£ã¦ãããã¯ãããã¾ããã
ä¸æ¹ãæå ¥éã«å¯¾ããç¸å¯¾æ¾å°æ§æ´»æ§ï¼%ï¼ã§è¦ãã¨ãåµå·£ã§ã¯ç¹ã«å¤ãä½ããªããæãé«ã48æéå¾ã®æ°å¤ï¼0.095%ï¼ã§ãã注å°çèé¨ä½ã§ã®0.004%ã«ããããã¾ããã§ããï¼è¡¨1å³ï¼ããã®ã¾ã¾ã ã¨é常ã«ä½ãå¤ã«æãã¾ãããããã¯ãèå¨ï¼çµç¹å ¨ä½ã®å¤§ããã»ééã®éãã«ãã£ã¦ããã®ãããªç¾ãæ¹ã«ãªããã¨ã«æ°ãã¤ããªããã°ãªãã¾ããã
ãã¨ãã°ãã©ããã®èèã¨åµå·£ã§ã¯ç´100åã®ééå·®ãããã¾ã [10]ãåç´ã«è¨ãæããã¨ã絶対éã¨ãã¦åµå·£ã§ã¯èèã®1/100éããæºã¾ãããããªãã®ã§ãããããã£ã¦ãåµå·£ã®æ¾å°æ§æ´»æ§ã®å¤ã100åï¼ãããã¯ééå½ããã®æ¯æ´»æ§ï¼ã«ãããã¨ã§ãåãã¦èèã¨æ¯è¼ã§ããã¨ãããã¨ã«ãªãã¾ãã
ããããã¨ã表1å·¦ã«ããè質ééã®ç¸å¯¾å¤ã¨è¿ããªãã¾ããã¤ã¾ããåµå·£ã«è質ããç²åãèç©ãã¦ããã¨ãããã¨ã¯è¡¨1å³ã®ãã¼ã¿ãããæºããã¾ããã
äºå®ããã¡ã¤ã¶ã¼ã®å½è©²ææ¸ã«ã¯ä»¥ä¸ã®ããã«è¨è¿°ããã¦ãã¾ãã
"Other than the site of administration, the liver was the highest and then detected in the spleen, adrenal and ovaries"
ï¼æå ¥ãããé¨ä½ä»¥å¤ã§ã¯ãèèã§ã®å¤ãæãé«ãã次ãã§è¾èãå¯è ãããã¦åµå·£ã«æ¤åºãããï¼
åå´çã®å ±åæ¸ã§ãããæä¸é¨ä½ä»¥å¤ã§æ¾å°è½ãèªãããã主ãªçµç¹ã¯ãèèãè¾èãå¯è åã³åµå·£ã§ãããæä¸8ï½48æéå¾ã«æé«å¤ï¼ãããã26ã23ã18åã³12 μg lipid eq./gï¼ã示ãããã¨ãªã£ã¦ãã¾ã [9] ã
ã§ã¯ããåµå·£ã«èç©ãã®åã«å¯¾ãã¦ããã ã¨è¨ã£ã¦ããæ²³é大è£ãããã° [1] ã§ã©ã®ããã«æ¸ãã¦ãããè¦ã¦ã¿ã¾ããããå³1注1ã«ç¤ºãããã«ãåµå·£ã§ã¯0.095%以ä¸ã¨èèã¨æ¯è¼ãã¦èããä½ããªãããã¼ã¯ã48æéã§ãããã¨è¿°ã¹ããèç©ã¨ããã®ã¯æããã«èª¤ãã§ããã¨æå®ãã¦ãã¾ãã
ãããããããã®æç« ã¯äºã¤ã®ç¹ã§èª¤è¬¬ãããã¾ããä¸ã¤ã¯ããã¼ã¯ã48æéãã¨è¨ã£ã¦ããã¨ããã§ãã48æé以ä¸ã¯èª¿ã¹ããã¦ããªãï¼å ¬è¡¨ããã¦ããªãï¼ã®ã§æ£ç¢ºã«è¨ãã°ãã¼ã¯ã¯åããããããªããã調ã¹ããã48æéã®ç¯å²å ã§ãã¨è¿°ã¹ãã¹ãã§ãã
ããä¸ã¤ã¯ãèè18%ãåµå·£0.095%ã¨æ¾å°æ§æ´»æ§æ¯çãåç´ã«æ¯è¼ãã¦ããèèã¨æ¯è¼ãã¦èããä½ããªãï¼ï¼ãã¨è¨ã£ã¦ããã¨ããã§ããä¸è¿°ããããã«ãèèã¨åµå·£ã®å¤§ããï¼ééï¼ã¯100åéãã®ã§ãæ¯è¼ãããªãééå½ããã®è質éï¼è¡¨1å·¦ï¼ã§è¿°ã¹ãã¹ãã§ãããã
å³1. è¡è°é¢è°å¡æ²³é太éå ¬å¼ãµã¤ãã®ãã¯ã¯ãã³ããã«ã¤ãã¦ãï¼[1]ããã®æç²ã«å çï¼.
æ²³é大è£ã®ããã°ã¯ããã¯ã¯ãã³æ¥ç¨®ã§éºä¼åãçµæãããããããæ²»é¨ãçµãã£ã¦ããªãã®ã§å®å ¨æ§ã確èªããã¦ããªããã¨ããåãçåã«å¯¾ãã¦ãçãã¦ãã¾ãããããããæ£ç¢ºæ§ã«æ¬ ãã¾ãã
ãmRNAã¯ç´°èã®æ ¸ã®å ¥ããã¨ãã§ããªããã¨ããã®ã¯ãä¸è¬çè«ä¸ã§ã¯ããã§ããããããã¬ããã¦ã¤ã«ã¹ï¼é転åæ´»æ§ããã¤RNAã¦ã¤ã«ã¹ï¼ãDNAã«å¤æããã¦ããã²ãã ã®ä¸ã«å ¥ããã¨ããRNAã¦ã¤ã«ã¹ã®ã¬ãããã¸ã·ã§ã³ç¾è±¡ãç¥ããã¦ããäºå®ããè¨ãã¨ï¼âæ°åã³ããã¦ã¤ã«ã¹ã®RNAãããã®DNAã«çµã¿è¾¼ã¾ããï¼ãå³å¯ã«è¨ãã°èª¤è§£ãä¸ããã¡ãã»ã¼ã¸ã§ãã
ã¾ããããªã¹ã¯ãä¸åãè¨åºçã«æå³ã®ããæå¹æ§ãã«ã¤ãã¦ã¯ããªã¹ã¯ã¨ãã¦ã®mRNAã¯ã¯ãã³ã®é篤æ害äºè±¡ãæ»äº¡ãã»ã¨ãã©è©ä¾¡ä¸è½ã¨ãã¦æ±ã£ã¦ããï¼ã¤ã¾ããªã¹ã¯è©ä¾¡ãã¼ã¿ããªãï¼åçå´åçã®ç¾ç¶ã«åºã¥ãã°ããªã¹ã¯/ãããã£ããæ¯ï¼ã¤ã¾ããæå³ã®ããæå¹æ§ï¼ãè¿°ã¹ããã¨ã¯å®éé£ããã§ãããªã¹ã¯ãä¸åãæå³ã®ããæå¹æ§ãè¨ããããªãã対象ã®ãªã¹ã¯ããã¡ãã¨è©ä¾¡ããã¦ããªããã°ãªãã¾ããã
æ害äºè±¡ãèµ·ããã¨ãããã¨ã«é¢é£ãã¦ãä¸è¿°ããããã«ãéºä¼åæ å ±ãåãè¾¼ãã ç´°èã§ã¿ã³ãã¯åæãèµ·ããããã»ã¹ã®å®å ¨æ§/æ害æ§ã«ã¤ãã¦ã¯ãã¾ã£ããããç´°èã§èª¿ã¹ããã¦ãã¾ãããã¿ã³ãã¯åæç´°èèªä½ãç´°èæ§å ç«ã®æ¨çã«ãªãå¯è½æ§ï¼âmRNAã¯ã¯ãã³ãåãã人ããæåã¿ã³ãã¯ã¨æä½ãæ¤åºï¼ãã¹ãã¤ã¯ã¿ã³ãã¯ã®æ¯æ§ã容æã«æ³åã§ããã«ãé¢ããããã§ãã
ä¸è¿°ããæ²³é大è£ã¨åãééãã¯ãã¯ã¯ãã³ã®ãããã¬ã³ããµã¤ãã§ããããã³ãããã§ãè¦ããã¨ãã§ãã¾ã [11]ã
3. Defenderã®è¨äºã§ã®ææ
Defenderã®è¨äº [8] ã«ããã°ããã¡ã¤ã¶ã¼ã®ãã¼ã¿ã«ã¤ãã¦ã精巣ã«ã¯è質ã®èç©ããã¾ããªããããåµå·£ã®ã·ã°ãã«ã¯ä¸å¯è§£ã§ãããã¨ããã¼ã³å士ã¯è¿°ã¹ã¦ãã¾ããã¾ããè質ããç²åã骨é«ããªã³ãç¯ãããæ¤åºããã¦ãããã¨ãããã¯ã¯ãã³æ¥ç¨®è ã®ç½è¡ç ããªã³ãè «ã®ã¢ãã¿ãªã³ã°ããã¹ãã¨ææãã¦ãã¾ãããããããã®ãããªã·ã°ãã«ã¯ãåå¹´ããæ°å¹´å ã¾ã§ç¾ããªããã¨ãå¤ãã¨ããã¢ãã¿ãªã³ã°ã®é£ãããããã¾ãã
ã¾ããããã¼ã³å士ã«ããã°ãé常ããã®ãããªã·ã°ãã«ã¯åç©å®é¨ãé·æã®è¨åºè©¦é¨ã§æ¤åºã§ãããã®ã®ãä»åã®mRNAã¯ã¯ãã³ã§ã¯èª¿ã¹ããã¦ããªãã¨ãããã¨ã§ããããã¦ããªãªã¸ãã«ã®ãã¼ã¿ããã±ã¼ã¸ã«ã¯ãã®è¬ç©åæ ç 究æ å ±ãå«ã¾ãã¦ããã¨ãããã¨ã§ãããå®éã¯ãä¸çä¸ã®è¦å¶å½å±ãä¿è·ãã¦ããéé示ã®ç¯å²å ã¨ãã¦å¦çããã¦ããã¨å½¼ã¯è¨ã£ã¦ãã¾ãã
ããã«ãããã¼ã³å士ã¯ãéé¢åã¹ãã¤ã¯ã¿ã³ãã¯ã®å±éºæ§ãFDAã«è¦åããå¤ãã®ç§å¦è ã®ä¸äººã§ãããç±³å½é£åå»è¬åå±ï¼FDAï¼ã¯ã¹ãã¤ã¯ã¿ã³ãã¯èªèº«ãçç©å¦çã«æ´»æ§ã§ããã注å°é¨ä½ãã移åãã¦æ害äºè±¡ãå¼ãèµ·ããå¯è½æ§ããããã¨ãç¥ã£ã¦ããã¨è¿°ã¹ã¦ãã¾ãã
å¯è½æ§ã¨ãã¦èãããããèªå·±å ç«åé¡ã§ãããèªç±ã«å¾ªç°ããã¹ãã¤ã¯ã¿ã³ãã¯ãé¢ä¿ãã¦ããã®ã§ã¯ãªããã¨å½¼ã¯ç¤ºåãã¾ããããéçºè ã¯ãã®ãããªãã¨ã¯èµ·ãããªãã¨æè¨ãã¦ãã¾ããèªå·±å ç«ã®å¯è½æ§ãæããã«ããããã«ã¯ãã¯ã¯ãã³ã«ããèªå·±å ç«ã®å½±é¿ãç£è¦ããããã®3ç¸ï¼ãã§ã¼ãºIIIï¼æ£è ã®2ï½3å¹´ã®ãã©ãã¼ã¢ããæéãå¿ è¦ã§ããããã¡ã¤ã¶ã¼ç¤¾ã¨ã¢ãã«ã社ã®ã¯ã¯ãã³ã§ã¯ããã®ãããªæ¤è¨ã¯ãªããã¦ãã¾ããã
ã¾ããããããã£ã¹ãã®å¯¾è«ç¸æã§ããã¯ã¤ã³ã¹ã¿ã¤ã³å士ã¯ããã¡ã¤ã¶ã¼ç¤¾ã¨ã¢ãã«ã社ã¯ãé©åãªåç©å®é¨ãè¡ã£ã¦ããªãã£ãã¨è¿°ã¹ã¦ãã¾ããéçºè ã®ãã¼ã¿ã«ã¯ãçæçã«ã¯ãã©ãã«è質ãããã®ããã©ãã«ã¹ãã¤ã¯ã¿ã³ãã¯ãããã®ãã¨ããç¹ã§ãããã¦æ害æ§ãæ»äº¡ççã®ç¹ã§ææ ®ãã¹ãã·ã°ãã«ããããèããéå°å ±åã§ããã¨èããããçç±ãããã«ããã¨è¿°ã¹ã¦ãã¾ãã
ã¯ã¤ã³ã¹ã¿ã¤ã³å士ã«ããã¨ãã¯ã¯ãã³ã«ããæ½å¨çãªå®³ã®ã²ã¨ã¤ã¯ãã¦ã¤ã«ã¹å¦è ã®ã´ã¡ã³ãã³ã»ããã·ã¥ï¼Vanden Bosscheï¼å士ã«ãã£ã¦æãã¿ã«ãªãã¾ãããããã¯ãããã·ã¥å士ãä¸çä¿å¥æ©é¢WHOã«å¯¾ãã¦ãä¸çè¦æ¨¡ã®å¤§è¦æ¨¡ãªã¯ã¯ãã³æ¥ç¨®ãã£ã³ãã¼ã³ã«ãã£ã¦ãæ½å¨çãªãå¶å¾¡ä¸è½ãªæªç©ããä¸çã«è§£ãæ¾ãããå¯è½æ§ãããã¨ã12ãã¼ã¸ã®ææ¸ã§å¼ã³ãããè¡ãªã£ããã¨ã§ããå¶å¾¡ä¸è½ãªæªç©ã¨ã¯å ç«ããããã¦ã¤ã«ã¹ã®ãã¨ã§ãã
ããªãã¡ãããã¯ãã¦ã³ã¨ãä¸ççãªå¤§è¦æ¨¡ãªã¯ã¯ãã³æ¥ç¨®ããã°ã©ã ã«ããã¦ã¤ã«ã¹ã¸ã®é¸æå§ã®çµã¿åããã«ãããçæçã«ã¯ææè æ°ãå ¥é¢è æ°ãæ»äº¡è æ°ã¯æ¸å°ããããããã¾ããããæçµçã«ã¯ããæ¸å¿µãããå ç«éé¿ã¦ã¤ã«ã¹å¤ç°ä½ãå¤ãçã¿åºããã¨ã«ãªããå¶å¾¡ä¸è½ãªç¶æ ã«ãªãå¯è½æ§ãããã¨ãããã¨ã§ããå ç«éé¿ãèµ·ããã¨ãã¯ã¯ãã³ä¼ç¤¾ã¯ã¯ã¯ãã³ãããã«æ¹è¯ãããã¨ãã¾ãããããã¯ããã«é¸æå§ãé«ãã¦ãã¾ããããã¾ã§ä»¥ä¸ã«æææ§ãé«ããæ»ã«è³ãå¯è½æ§ã®ããå¤ç°ä½ãçã¿åºããã¨ã«ãªãã¾ãã
ãã®ãããªå ç«åé¿ã®åé¡ã¯ãç§ãå«ãã¦è¬å¤èæ§èã®å®ä¾ãç¥ã£ã¦ããå¾®çç©å¦è ãªãããã«æ³åãã¤ãã¾ããæçç©è³ªã®ä½¿ç¨ã«ãã£ã¦ãããé¸æå§ã«ãªãããã£ã¨å¼·åãªè¬å¤èæ§èãçã¾ããã¨ããç¾å®ã¯ã人é¡ãç´é¢ãã¦ãã大ããªåé¡ã§ããCOVID-19ã¯ã¯ãã³ãå¤ç°ä½ã®åºç¾ãä¿ããæææ¡å¤§ãããã¨ããã®ã¯ãããã¦ç¾å®çãªã·ããªãªã§ãã
ãããã«
ä¸è¿°ããããã«ãå ¬éããããã¡ã¤ã¶ã¼ç¤¾ã®è¬ç©åæ 解æãã¼ã¿ããã¯ãmRNAãå ãè質ããç²åãçè注å°ãããã©ãããããããåµå·£ãå«ããã¾ãã¾ãªèå¨ã«èç©ãããã¨ãæãããªããã«è¦ãã¾ããããã¯mRNAã¯ã¯ãã³ã®æ¸å¿µããã課é¡ã¨ãã¦ãæ©æ¥ã«ããã®è¨åºç 究ã§æ¤è¨ããã¹ãã§ãããã
ã¹ãã¤ã¯ã¿ã³ãã¯è³ªã®æ¯æ§ã«ã¤ãã¦ããç¾æ®µéã§ã¯ç¢ºå®ãªç§å¦ç証æ ã¯ãªããããæ±ãããã¦ãã¾ãããç¶æ³è¨¼æ ã¯æ¯æ§ã®çããæ¿ããã®ã«ãªã£ã¦ãã¾ããmRNAãä½ãããæåã¿ã³ãã¯ã®ä½å ã§ã®åæ ã¨ã¨ãã«ãç·æ¥ã®æ¤è¨ãè¦ããç 究課é¡ã ã¨æããã¾ãã
ããã¦ãå©æ¨©ã絡ãã¨ãã¦ã¤ã«ã¹å¤ç°ä½ã«å¿ãã¦è¨æ©å¿å¤ã«ã¯ã¯ãã³ãæ¹è¯ãããã¨ãªããè¨ãã°å¨åº«å¦åã®ããã«ãç¹°ãè¿ãã®æ¥ç¨®ï¼ãã¼ã¹ã¿ã¼ï¼ã¨ãããã¨ã§å¯¾å¦ãããã¨ã«ãªãã§ããããããã¯éä¸åæä½ã®ç£çãä¿ããæä½ä¾åæ§å¢å¼·ï¼ADEï¼ãèªå·±å ç«ç¾æ£ã«ç¹ããå¯è½æ§ãããã¾ãã
ãã¾ã¯ã¯ãã³æ¥ç¨®ã¯ã¹ã©ã ãã³ã¯ç¶æ ã§ãããå½çã«å¯¾ãã¦ã¢ããè¨ããã¨ã¯ãæ²³é大è£ã®ããã°ã«ãããããã«ã容æã«ããæ±ãããã¦ãã¾ããããªã¿ããªè¡çºã§ãããªã¹ã¯ã«å¯¾ããå©çãç¾ã«ã¯ã¯ãã³æ¥ç¨®ãä¿ã声ã¯å¤§ããã§ãããä¸è¿°ããããã«ã¯ã¯ãã³æ¥ç¨®ã«é¢ããé篤æ害äºè±¡ãæ»äº¡ã«ã¤ãã¦ã¯ã»ã¨ãã©è©ä¾¡ããã¦ãããããã®ããã§ãªã¹ã¯/ãããã£ããæ¯ãå®éçã«è«ãããã¨èªä½ãæ¥æ¬ã§ã¯é£ããã§ããã ãããããã¯ã¯ãã³æä¾å´ãæ¨é²æ´¾ããã®æ 宣役ã®ã¡ãã£ã¢ [2] ã«ããéã®ã¤ã³ãã©ãããã¯ã«ã¯æ³¨æããããã®ã§ãã
å¼ç¨æç®ã»è¨äº
[1] è¡è°é¢è°å¡æ²³é太éå ¬å¼ãµã¤ã: ã¯ã¯ãã³ããã«ã¤ãã¦.2021.06.24. https://www.taro.org/2021/06/%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E3%83%87%E3%83%9E%E3%81%AB%E3%81%A4%E3%81%84%E3%81%A6.php
[2] ç±æºåºå¤ª: æ²³éæ å½ç¸ã7ã¤ã®ãã¯ã¯ãã³ããããããã°ã§å¦å®ããå»å¸«ã«ããããããæµã人ããã¨æ³¨æå¼ã³ãã. BuzzFeed News 2021.06.24. https://www.buzzfeed.com/jp/kotahatachi/taro-kono-blog
[3] Kertscher, T.: No proof for researcher claim that COVID-19 vaccinesâ spike protein is a âtoxinâ. POLITIFACT June 7, 2021. https://www.politifact.com/factchecks/2021/jun/07/facebook-posts/no-proof-researcher-claim-covid-19-vaccines-spike-/
[4] Carballo-Carbajal, I.: Byram Bridleâs claim that COVID-19 vaccines are toxic fails to account for key differences between the spike protein produced during infection and vaccination, misrepresents studies. Health Feedback June, 8, 2021. https://healthfeedback.org/claimreview/byram-bridles-claim-that-covid-19-vaccines-are-toxic-fails-to-account-for-key-differences-between-the-spike-protein-produced-during-infection-and-vaccination-misrepresents-studies/
[5] Dupuy, B.: Spike protein produced by vaccine not toxic. AP NEWS June 10, 2021. https://apnews.com/article/fact-checking-377989296609
[6] Grobbelaar, L. M. et al.: SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: Implications for microclot formation in COVID-19. medRxiv Posted Mar. 8, 2021. https://www.medrxiv.org/content/10.1101/2021.03.05.21252960v1.full
[7]Â Lei, Y.: SARS-CoV-2 spike protein impairs endothelial function via downregulation of ACE 2. Cir. Res. 128, 128:1323â1326 (2021). https://doi.org/10.1161/CIRCRESAHA.121.318902Â
[8] Redshaw, M.: Inventor of mRNA technology: Vaccine causes lipid nanoparticles to accumulate in âhigh concentrationsâ in ovaries. Defender 2021.06.17. https://childrenshealthdefense.org/defender/mrna-technology-covid-vaccine-lipid-nanoparticles-accumulate-ovaries/
[9] åçå´åçå»è¬ã»çæ´»è¡çå±å»è¬å審æ»ç®¡ç課ï¼å¯©è°çµæå ±åæ¸. 2021.02.12. https://www.mhlw.go.jp/content/10601000/000739089.pdf
[10] ç°æä½å¤ªéã:ã©ããã®ä½éã®èå¨ééã«ã¤ãã¦. åé¢æ±å»å¦ï¼åé¢æ±å»å¦ä¼ï¼ 12(7), 250â265 (1962). https://www.jstage.jst.go.jp/article/kmj1951/12/4/12_4_250/_pdf
[11] ãã³ãã: ã¯ã¯ãã³Q&Aï¼ã¿ãªããã¸. https://covnavi.jp/category/faq_public/
å¼ç¨ããæèããã°è¨äº
2021å¹´6æ27æ¥Â COVID-19ã¯ã¯ãã³ã¯å¦å¨ ãçæ®ã¸ã®å½±é¿ããããï¼
2021å¹´6æ26æ¥Â æ ¸é ¸ã¯ã¯ãã³ã¸ã®çåã¼ããã¼ã³å士ã®ä¸»å¼µãèãã
2021å¹´5æ27æ¥ mRNAã¯ã¯ãã³ãåãã人ããæåã¿ã³ãã¯ã¨æä½ãæ¤åº
2021å¹´5æ15æ¥Â æ°åã³ããã¦ã¤ã«ã¹ã®RNAãããã®DNAã«çµã¿è¾¼ã¾ãã
ããããããããããããããã
ã«ãã´ãªã¼ï¼ææçã¨COVID-19